Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): study protocol for a randomised controlled trial
Abstract Background Dual antiplatelet therapy (DAPT) with aspirin (ASP) and a P2Y12 blocker is currently standard care after percutaneous coronary intervention (PCI) with stent insertion, and aims to inhibit platelet function in order to prevent stent thrombosis. The P2Y12 blocker ticagrelor (TIC) h...
Main Authors: | Sarah Baos, Wendy Underwood, Lucy Culliford, Barnaby C. Reeves, Chris A. Rogers, Ruth Bowles, Tom Johnson, Andreas Baumbach, Andrew Mumford |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-11-01
|
Series: | Trials |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13063-017-2277-9 |
Similar Items
-
Ticagrelor
by: Gianluca Airoldi, et al.
Published: (2013-03-01) -
No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
by: Viviana Laredo, et al.
Published: (2020-05-01) -
Ticagrelor versus clopidogrel in the management of acute myocardial infarction
by: Candice Volney, et al.
Published: (2019-07-01) -
A cost-effectiveness and safety analysis of dual antiplatelet therapy comparing aspirin–clopidogrel to aspirin–ticagrelor in patients with acute coronary syndrome
by: Nafrialdi Nafrialdi, et al.
Published: (2018-12-01) -
Clopidogrel in the treatment of patients with ST-elevation acute myocardial infarction: state-of-art in 2013
by: O. V. Averkov
Published: (2013-02-01)